Reference
Kim J, et al. Response to amivantamab, a bispecific EGF and MET receptor directed antibody, in a patient with an atypical EGFR mutated (G719X) non-small cell lung cancer (NSCLC) with leptomeningeal disease who progressed on Osimertinib. Cancer Research 82 (Suppl.): No. 12, 15 Jun 2022. Available from: URL: http://doi.org/10.1158/1538-7445.AM2022-4113 [abstract]
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1921, 35 (2022). https://doi.org/10.1007/s40278-022-22029-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-22029-1